Equities analysts expect that Applied Genetic Technologies Corp (NASDAQ:AGTC) will announce earnings per share of ($0.25) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Applied Genetic Technologies’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.31). Applied Genetic Technologies posted earnings per share of ($0.05) in the same quarter last year, which suggests a negative year-over-year growth rate of 400%. The company is scheduled to issue its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Applied Genetic Technologies will report full year earnings of ($1.30) per share for the current year, with EPS estimates ranging from ($2.38) to ($0.63). For the next year, analysts anticipate that the business will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.52) to ($1.18). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Applied Genetic Technologies.
Applied Genetic Technologies (NASDAQ:AGTC) last announced its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.20). The business had revenue of $4.85 million during the quarter, compared to analyst estimates of $8.72 million. Applied Genetic Technologies had a negative net margin of 33.24% and a negative return on equity of 9.21%. The firm’s revenue for the quarter was down 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share.
Shares of Applied Genetic Technologies (NASDAQ:AGTC) remained flat at $$4.40 during trading hours on Wednesday. 20,605 shares of the stock traded hands, compared to its average volume of 110,937. The company has a market capitalization of $77.85, a price-to-earnings ratio of -7.33 and a beta of 2.18. Applied Genetic Technologies has a 1-year low of $3.25 and a 1-year high of $7.83.
A number of institutional investors have recently modified their holdings of AGTC. Dimensional Fund Advisors LP increased its position in Applied Genetic Technologies by 66.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 266,441 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 106,558 shares in the last quarter. ClariVest Asset Management LLC increased its position in Applied Genetic Technologies by 18.5% in the 3rd quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 15,491 shares in the last quarter. Citadel Advisors LLC increased its holdings in Applied Genetic Technologies by 304.6% during the 3rd quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 31,070 shares in the last quarter. Spark Investment Management LLC increased its holdings in Applied Genetic Technologies by 122.1% during the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 59,200 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Applied Genetic Technologies by 32.5% during the 4th quarter. Renaissance Technologies LLC now owns 444,428 shares of the biotechnology company’s stock worth $1,600,000 after purchasing an additional 109,128 shares in the last quarter. 46.03% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/applied-genetic-technologies-corp-agtc-expected-to-announce-earnings-of-0-25-per-share.html.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.